During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Series A funding round led by Angelini Ventures’, the investment arm of Italian industrial group Angelini Industries. The ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Gilead’s CAR-T cancer therapy has been approved in the US for an aggressive form of blood cancer, indicating the company’s $12 billion acquisition on Kite Pharma could pay off. Priced at $ ...

Kash is known to Israelis mainly for his books "Success Tactics You Won't Learn in Business School" "Freedom from Disease" ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

Synopsis: In a case with implications for the litigious molecular diagnostics space and written description law, Chief Judge Connolly ...

As principal and co-founder of Sierra Pacific Constructors and a second-generation builder, Cary Gerhardt remains active in ...

Sierra Pacific Constructors principal and cofounder Ken La Spada is responsible for a wide diversity of activities for SPC, ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...